An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Notoriously hard to treat, pancreatic and colorectal cancers each have high recurrence rates in the years following treatment ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back.

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task ...

A new off-the-shelf peptide vaccine has proven effective against pancreatic and colorectal cancer, reducing the chances of ...

Black and Hispanic people are more likely to be diagnosed with pancreatic cancer and more likely to die from it. Now, one drug may help fix this.